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Abbreviations 
ACN – acetonitrile  
AM – acetoxymethyl 
ATP – adenosine 5’-triphosphate 
BODIPY FL – 4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-propionic acid 
Boc – tert-butyloxycarbonyl 
CAMK – calcium/calmodulin-dependent protein kinase 
DCE – 1,2-dichloroethane  
DIC – N,N'-diisopropylcarbodiimide 
DIPEA – N,N-diisopropylethylamine 
DMEM – Dulbecco’s modified eagle medium 
DMF – dimethylformamide  
DMSO – dimethyl sulfoxide 
DTT – dithiothreitol 
EDTA – ethylenediaminetetraacetic acid 
ESI-MS – electrospray ionization mass spectrometry 
FA – fluorescence anisotropy 
FBS – fetal bovine serum 
Fmoc – fluorenylmethyloxycarbonyl 
FRET – Förster resonance energy transfer 
GTP – guanosine 5’-triphosphate 
HBSS – Hank's Balanced Salt Solution 
HBTU – N,N,N′,N′-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate 
HeLa – cervical cancer cells derived from Henrietta Lacks 
HEPES – 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HOBt – hydroxybenzotriazole  
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HPLC – high-performance liquid chromatography 
HRMS – high-resolution mass spectrometry 
IC50 – half-maximal inhibitory concentration 
ICR – ion cyclotron resonance 
Kd – equilibrium dissociation constant determined from a displacement assay 
KD – equilibrium dissociation constant determined from a direct binding assay 
Ki – equilibrium dissociation constant determined from an inhibition assay 
Km – Michaelis constant 
MS – mass spectrometry 
Nala – N-methylglycine 
Nasp – N-carboxymethylglycine 
NHS – N-hydroxysuccinimide 
Nlys – N-4-aminobutylglycine 
NMM – N-methylmorpholine  
NSG – N-substituted glycine oligomers 
NTP – nucleoside triphosphate 
PBS – phosphate-buffered saline 
PNBP – 4-(4-nitrobenzyl)pyridine 
RPMI – Roswell park memorial institute medium 
SPPS – solid phase peptide synthesis 
TBBi – 4,5,6,7-tetrabromo-1H-benzimidazole 
TBBi-oca – 8-(4,5,6,7-tetrabromo-1H-benzimidazol-1-yl)octanoic acid 
TFA – trifluoroacetic acid 
TK – tyrosine kinase 
TKL – tyrosine kinase-like 
TIPS – triisopropylsilane 
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1. Introduction 
Phosphorylation of proteins is one of the most important processes in living cells. 
Phosphorylation can induce signalling and change enzymatic activity. Enzymes, which 
catalyse the transfer of a phosphoryl group from nucleoside triphosphate (NTP) to protein, are 
called protein kinases.  
CK2 is a unique protein kinase differing from other kinases in several aspects. CK2 has many 
substrates in a human organism and it accepts both ATP (adenosine triphosphate) and GTP 
(guanosine triphosphate) as a phosphoryl group donor. CK2 is active in the form of free 
catalytic subunit and as holoenzyme. It is acidophilic, meaning that it recognizes substrates 
that contain negatively charged amino acid residues around the phosphorylatable residue. The 
increased activity of CK2 is associated with many diseases, most frequently with cancer, 
which makes CK2 a target for pharmacy.  
Asko Uri research group has developed bisubtrate ARC-type inhibitors with high affinity 
towards CK2. The compounds are negatively charged in physiological environment as they 
contain several aspartate residues. 
A cell membrane is a negatively charged phospholipid bilayer therefore it allows the 
permeation of positively charged compounds and hydrophobic molecules. This complicates 
the introduction of compounds containing aspartate residues into cells. One possibility to lead 
highly charged compounds into cells is to mask the negative charges of the former, e.g. with 
the esterification of the carboxylates. This modification endows the compounds with cell 
membrane penetrative properties. Once the esterified compound is inside a cell, intracellular 
esterases cleave the ester groups and the compound will be trapped inside the cell in an active 
form.  
The aim of this master’s thesis was to synthesize a cell permeable esterase-activated CK2 
bisubstrate inhibitor, determine its ability to penetrate the cell membrane and examine its 
intracellular stability.  
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2. Literature overview 
2.1. Protein kinases 
Protein kinases are enzymes that catalyse the transfer of phosphoryl group from nucleoside 
triphosphate (NTP) to a hydroxyl group of an amino acid residue in a protein (Figure 1). 
Phosphorylation causes alterations in the protein shape by adding several negative charges 
into the structure of the latter, which leads to development or loss of further interactions. The 
reaction in which a phosphate group is removed from the protein is called dephosphorylation 
and is regulated by enzymes called phosphatases. Thereby, protein kinases and phosphatases 
influence many mechanisms and reaction pathways through the regulation of phosphorylation 
equilibrium. 
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Figure 1. γ-phosphoryl group transfer from ATP to protein. R – Ser, Thr or Tyr residue. 
The genes of over 500 known protein kinases make up about 2% of human genome [1]. Most 
of the protein kinases phosphorylate serine or threonine residues and ca 90 kinases are 
specialized in phosphorylation of tyrosine residues [1]. Additionally, there are a few 
dual-specificity kinases, which have the ability to phosphorylate both serine/threonine and 
tyrosine residues [2]. Most protein kinases use ATP as a phosphoryl group donor, but few 
kinases are able to utilize guanosine triphosphate (GTP) and other nucleotides on that 
purpose, although with a lower efficiency [3, 4].  
Eukaryotic protein kinases are divided into groups, families and subfamilies based on amino 
acid sequence of the catalytic domain, biological functions and substrate specificities [5, 6]. 
Kinases in AGC group need to be activated by secondary messengers (cyclic nucleotides, 
phospholipids etc.) and they catalyse the transfer of phosphoryl group to the hydroxyl group 
of serine/threonine preferably near basic amino acid residues [7]. 
Calcium/calmodulin-dependent protein kinase (CAMK) group contains kinases that are 
regulated by Ca
2+
/calmodulin [7]. In CMGC group, there are kinases that phosphorylate 
substrates rich in proline residues [7]. CK1 group was named after casein kinase 1 and it 
phosphorylates sequences containing many acidic residues [6]. STE group includes kinases 
that are involved in with activation of MAPK and related kinases [5]. Tyrosine kinase (TK) 
group kinases phosphorylate tyrosine residues and tyrosine kinase-like (TKL) kinases are 
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serine/threonine kinases structurally similar to TK kinases [5]. There are in addition atypical 
kinases, which have unusual structure, e.g. transmembrane receptors, with an intracellular 
kinase domain [6].  
Protein kinases are essential biological catalysts, which strongly affect the life of cells by 
different mechanisms. They can be involved in enzyme activation and inactivation, protein 
localization, stabilization, degradation etc. The malfunction of protein kinases is associated 
with several serious diseases including cancer, which is the reason why protein kinases have 
become one of the targets of pharmacy. The activity of protein kinases can be suppressed with 
inhibitors. As of 2013, 26 small molecule inhibitors of protein kinases were approved for 
clinical use and several were in advanced clinical trials [8]. These inhibitors are mostly 
targeted at cancer, but also at rheumatoid arthritis and myelofibrosis. Altogether, about 
50-70% of the current cancer targeted drug research are focused on inhibitors of protein 
kinases [8].  
The majority of protein kinase inhibitors are targeted to the ATP binding site of the enzyme 
(Type I inhibitors). As ATP concentration in cells is in the millimolar range, it is relatively 
difficult for ATP competitive inhibitors to efficiently inhibit the kinase [9]. Another major 
drawback of ATP-competitive inhibitors is their low selectivity due to highly conserved ATP 
binding region in different kinases, which might result in possible side effects. Acquirement 
of selectivity for ATP competitive inhibitors is very challenging, although not impossible [9]. 
Sometimes lack of specificity is not a drawback, because it might enable to use the inhibitor 
against several PKs within the same pathway contributing to one disease [8]. Another class, 
Type II inhibitors, prevent the activation of PK by binding to an inactive form of the enzyme. 
Type II inhibitors have a better potency in vivo than Type I inhibitors, because ATP does not 
bind to the inactive conformation of the kinase. Bisubstrate inhibitors are active site targeted 
inhibitors, which consist of two fragments and each fragment binds to a targeted binding site. 
The advantage for competing with two substrates is the ability to create more interactions 
with the target enzyme and hence give a better inhibition potency and selectivity.  
2.2. Protein kinase CK2 
Protein kinase CK2, previously known as casein kinase 2, is a ubiquitous and constitutively 
active protein kinase, which is evolutionally highly conserved [10]. Two regulatory subunits β 
(26-42 kDa each) consolidate two catalytic subunits (α or α’) into a heterotetrameric 140 kDa 
holoenzyme (α2β2, α’2β2, αα’β2, Figure 2) [10-11]. Catalytic isoforms α (42-44 kDa) and α’ 
(38 kDa) are structurally different to the extent of 25% of amino acid sequence, however their 
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activities do not vary significantly [10, 12]. CK2 catalytic subunits are active with or without 
the presence of β subunits, but the tetrameric structure of CK2 is more stable and its activity is 
generally even higher when compared to the free catalytic subunits [11, 13]. Both types of 
CK2 catalytic subunit are related to CMGC group kinases, but possess distinguishable 
sequences [10]. CK2 has many basic amino acid residues in its catalytic domain to interact 
with substrates containing several acidic amino acid residues [10]. No other kinases in CMGC 
group display such acidophilicity and unlike other CMGC group kinases, CK2 does not need 
to be phosphorylated to be maximally active [10]. Regulatory subunits influence the peptide 
substrate selectivity towards CK2; for example, CK2 holoenzyme does not phosphorylate 
calmodulin, whereas the catalytic α subunit does [14]. CK2β contains a zinc-binding motif 
called zinc-finger, which helps to create a highly stabilized holoenzyme once Zn
2+
 ions are 
bound [15]. The holoenzyme complex has a low nanomolar dissociation constant value and 
therefore displays high stability [13]. It is proposed that with the assistance of β subunits, 
supramolecular assembly of three holoenzymes is generated, which regulates the activity of 
CK2 [11]. 
 
Figure 2. Holoenzyme of CK2. Green and blue domains depict α subunits, violet and yellow 
domains depict β subunits and grey spheres depict Zn2+ ions (PDB 4DGL). 
CK2 is a pleiotropic kinase, which means it is able to transfer a phosphoryl group to many 
different substrates. It is proposed that about 20% of a human phosphoproteome is 
phosphorylated by CK2 [16]. The consensus sequence of phosphoacceptor sites of CK2 
substrates is (E/D/x)-(S/T/Y)-(D/E/x’)-(E/D/x)-(E/D)-(E/D/x), where S/T/Y is the acceptor of 
phosphoryl group, x is any residue except basic residues and x’ additionally excludes proline 
residue [17]. The most important residue for efficient binding is at the position n+3, which is 
found in 90% of sites [17]. The second most important residue lies at position n+1 and is 
found in 75% of the sites. When an acidic residue is missing at the position n+3, then it is 
always at the position n+1 and vice versa [17]. Basic residues at positions between n-1 to n+4 
are not well tolerated and have a negative effect on the affinity between the substrate and CK2 
[17]. Phosphoserine can replace Glu and Asp residues in every position. On average, there are 
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over five negatively charged side chains in the phosphoacceptor site of a protein, which is 
phosphorylated by CK2 [17].  
Like most protein kinases, CK2 transfers the phosphoryl group to a serine or threonine 
residue, but in addition, CK2 is also capable of phosphorylating tyrosine [18]. CK2 can 
efficiently utilize both ATP and GTP as a phosphoryl group donor [3, 10, 19]. The Km value 
of CK2 for ATP (6-12 μM) is slightly lower than for GTP (9-21 μM) [19]. As a few hundred 
substrates of CK2 is known, the kinase is involved in many cellular processes such as 
protection against cellular stress, transcriptional control, cell cycle and neural functioning 
[20]. CK2 is found in most mammalian cells and furthermore, CK2 is present nearly 
everywhere inside a cell [21]. Many research groups have detected CK2 in plasma membrane, 
cytoplasm, mitochondria, endoplasmic reticulum, cytoskeleton, centrosomes and nucleus 
[21]. It is thought that the subcellular localisation of CK2 is a dynamic process and can be 
altered depending on the requirement for the kinase at specific sites inside a cell [21].  
Involvement of CK2 in many diseases has been reported: increased activity of CK2 is 
observed in cancer cells but also in several neurodegenerative diseases like Parkinson’s and 
Alzheimer, cardiovascular and inflammatory diseases, viral and parasite infections [20]. The 
excessive activity of the kinase correlates with its over-expression [20]. It is thought that CK2 
is neither the direct cause nor the consequence of a neoplastic transformation, but it provides a 
suitable environment for cancer [22]. CK2 generates pro-survival signals in cancer cells, 
which are vital for malignant cells dependent on defective apoptosis [22]. As the transformed 
cell becomes addicted to high levels of CK2, the suppression of the kinase activity can lead to 
apoptosis of the cell [22].  
In order to decrease the abnormally elevated activity of CK2, inhibitors targeting this kinase 
can be applied. An example of a potent type I CK2 inhibitor is CX-4945, which has recently 
completed the Phase I clinical trial and entered Phase II [23, 24]. CX-4945 is an orally 
bioavailable inhibitor with a Ki value of 0.38 nM (Figure 3) [25]. The inhibitor is very 
selective as only 7 kinases out of 238 tested were inhibited more than 90% at 500 nM 
concentration of CX-4945 [26]. The clinical trial proved that CX-4945 can be administered 
safely to humans [23]. During the drug administration, the stolid tumor stabilized for at least 
16 weeks [23].  
Other examples of type I CK2 inhibitors are polyhalogenated benzimidazole and 
benzotriazole derivatives, which have shown high affinity towards this kinase [20]. For 
example, 4,5,6,7-tetrabromo-1H-benzimidazole (TBBi) has a Ki value towards CK2 0.5 μM 
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(Figure 3) [27]. There are several other structures that are under development for CK2 
inhibitors, which are based on the scaffolds of flavonoid, coumarin, anthraquinone, 
xanthenone etc. [20]. Because of constitutive activity of CK2, type II inhibitors for CK2 have 
not been reported. [20].   
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Figure 3. Structures of CX-4945 (A) and TBBi (B). 
2.3. ARC-type inhibitors 
ARC-type (previously abbreviated from adenosine analogue oligoarginine conjugate) 
inhibitors developed by Asko Uri research group are probably the most profoundly studied 
bisubstrate inhibitors of protein kinases [28]. ARCs are conjugates, where a fragment targeted 
at ATP binding cleft (usually aromatic heterocycle) and peptidic fragment are interconnected 
with a hydrophobic linker. ARC-type inhibitors are highly potent inhibitors with a great 
selectivity and the most potent compounds have their inhibition constants in the one-digit 
picomolar range [29]. 
ARC-1028
MW = 1572 
IC50 = 5.3 nM (PKAc, 1 mM ATP)
O
O
OH
OH
NH
O
NH-(D-Lys)NH
NH (D-Arg)6CONH2
O
N
N
N
N
NH2  
Figure 4.  The third generation of ARC-type inhibitors [28].  
The first generation of ARC-type inhibitors included adenosine and oligo-L-arginine attached 
via an aminohexanoic linker. The development of second generation ARCs included 
amidation of the C-terminus to remove the negative charge, which caused three- to fivefold 
increase in the inhibition potency [28]. The breakthrough in the development was the 
replacement of L-amino acids with D-amino acids, which increased the inhibition potency up 
to 100 times and also increased the proteolytic stability [28]. An extended linker with a chiral 
centre was inserted to the third generation of ARC-type inhibitors and this modification 
allowed a better binding between the inhibitor and the enzyme with a Kd value down to 
one-digit picomolar range (Figure 4) [29].  
A) B) 
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The specimens of the first generation of ARC-type inhibitors were successfully applied in cell 
experiments [30]. The oligoarginine constituent of an ARC-type inhibitor resembling a cell 
penetrating peptide promoted the conjugate to penetrate the plasma membrane, yet probably 
several different mechanisms of permeation were involved [30].  
ARC-type inhibitors can be used as biosensors as they preserve high affinity even after tagged 
with a fluorescent marker [31]. Their affinity and selectivity can be adjusted by variation of 
their peptidic moiety, nucleosidic fragment or linker. Special type of ARC-type inhibitors 
incorporate thiophene or selenophene ring that after binding to a target kinase, produce a long 
lifetime photoluminescence signal upon excitement at near-UV region [32]. When a 
compatible fluorescent dye is attached to the probe, signal amplification occurs as a result of 
Förster resonance energy transfer (FRET) from the phosphorescence donor (thiophene or 
selenophene ring) to the fluorescent acceptor (fluorescent dye) [32]. This phenomenon is 
likely to occur with all protein kinases and it has great potential for real-time measurements of 
binding events in cells [32]. 
Recently, the bisubstrate inhibitor approach has been used for designing ARC-type inhibitors 
for CK2 [33]. Unlike ARCs targeted at basophilic kinases and containing an oligoarginine 
fragment, ARCs targeted at acidophilic CK2 contain negatively charged amino acids. Up to 
date the best disclosed bisubstrate inhibitor of CK2 is ARC-1502, which incorporates an 
oligoaspartate peptide, lysine residue for a dye attachment, octanoic acid linker and TBBi 
(Figure 5) [33]. The Kd value of ARC-1502 is in subnanomolar range (Kd = 0.52 nM), very 
similar to the Kd value of CX-4945 (Kd = 0.56 nM) [33]. The comparison of the affinities of 
ARC-1502 and its parent compound TBBi (Ki = 0.5 μM) towards CK2 shows clearly that 
ARC-1502 is much more potent CK2 inhibitor [27]. ARC-1502 is also more selective towards 
CK2 than TBBi, as only 10 kinases out of 140 in the selectivity panel were inhibited more 
than 50% while the residual activity of CK2 was 1% at 1 μM concentration of ARC-1502 
[33]. The inhibition of several basophilic kinases such as Pim-1 and Pim-2 was observed with 
the parent compound TBBi, but not with ARC-1502, illustrating the high potential of 
bisubstrate approach for improving the selectivity of inhibition [33]. A fluorescent dye 
PromoFluor-647 was attached to ARC-1502 yielding a fluorescent ligand ARC-1504, which 
was demonstrated to be applicable in displacement assays to determine the affinities of 
non-labelled inhibitors of CK2 [33].  
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Figure 5. Structures of ARC-1502 (R = X) and ARC-3138 (R = Y). 
Another ATP pocket-binding fragment benzoselenadiazole was introduced to yield a 
long-lifetime photoluminescent probe for CK2 [34]. ARC-3138 (Kd = 82 nM) emits 
luminescence in complex with CK2 while no long lifetime luminescence is emitted by the 
free ligand (Figure 5) [34].  
2.4. Ester-loading technique for cellular delivery of anionic compounds  
The plasma membrane consists of two layers of phospholipids and proteins embedded inside. 
It is a hydrophobic barrier that separates the interior of the cell from the exterior. Unfamiliar 
ionic and polar compounds are generally incapable of permeating the plasma membrane, 
while essential ions and other polar molecules can permeate the membrane by the aid of 
transporters. There are several techniques for the introduction of membrane impermeable 
compounds to cells such as electroporation, microinjection and cell penetrating peptide 
mediated cargo delivery. 
A prodrug approach based on AM esters is often used to introduce negatively charged 
molecules inside cells [35-37]. These esters are membrane-permeable and they can be 
introduced to cell by simply applying the esters to extracellular medium [38]. Once inside the 
cell, acetyl group is  on-ionic  in esterase-catalyzed reaction and the hydroxymethyl ester is 
spontaneously cleaved releasing  on-ioni and carboxylic acid (Figure 6). The molecule is 
incapable of leaving the cell resulting in increase of concentration of the compound inside 
cells [38]. The de-esterification is dependent on the concentration of the compound, time and 
temperature of incubation. 
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Figure 6. Hydrolysis of an AM ester. 
Methanal and acetic acid are produced as side products, but their concentrations are low and 
therefore do not influence remarkably cellular processes [38]. This has been confirmed for 
several penicillin prodrugs (such as pivampicillin) that are acyloxymethyl esters (Figure 7) 
[39].  
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Figure 7. Structures of penicillin prodrug pivampicillin (A) and Fura-2 AM ester (B) [39]. 
As masking with AM esters changes the esterified compound more hydrophobic, the aqueous 
solubility of the compounds is decreased and the stock solutions of the compounds are usually 
made in dimethyl sulfoxide (DMSO) [40]. Additionally, surfactants like Pluronic F-127, 
which is a  on-ionic dispersing agent, are frequently used to aid the dispersion of compounds 
containing AM esters in aqueous solutions to prevent precipitation [40].  
Probably one of the most widespread fields of AM ester application is reducing the polarity of 
calcium indicators for cell internalization [40]. Fura-2 is a fluorescent dye that changes its 
absorption spectrum when bound to calcium (Figure 7) [40]. For cell permeation its five 
carboxylates are masked with AM esters [40].  
Compared to more invasive techniques like electroporation and microinjection, the prodrug 
approach is a milder technique to introduce polar compounds to cells. A disadvantage of 
using AM esters for plasma membrane permeation of a compound is the incomplete 
hydrolysis of ester bonds [41]. The possible reasons for the incomplete de-esterification can 
be low activities of esterases and different rate constants for hydrolysis of AM esters at 
different positions. Another disadvantage of using AM esters is the possibility of 
accumulation in organelles [41]. A problem observed during the application of Fura-2 is the 
leakage of the compound out of the cells due to action of anion transporters. The leakage can 
be suppressed by anion transport inhibitors [41].  
2.5. Solid-phase peptide synthesis (SPPS) 
SPPS is the most widespread strategy for peptide synthesis. The synthesis is carried out on an 
insoluble polymer, e.g. cross-linked polystyrene resin [42]. The resin contains functional 
groups, which are the reaction centres for the first step of the synthesis. A resin loading is the 
amount of functional groups per mass unit of the resin.  
Synthesis usually starts from the attachment of the most C-terminal amino acid residue of the 
peptide of interest and is carried out in repeated cycles (Figure 8) [43]. Each amino acid 
addition requires two steps: deprotection of N-terminal amino acid and attachment of the new 
A) B) 
14 
 
amino acid to the N-terminal of the peptide. Every amino acid is added in excess in order to 
accelerate the reaction and to enhance the yield. In order to remove the reagent surplus, resin 
is washed after every amino acid attachment.  
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Figure 8. SPPS. PG – protection group, LG – leaving group 1) Attachment of the first amino 
acid to the resin. 2) Removal of the protection group PG from the α-amine. 3) Activation of 
the protected amino acid. 4) The formation of peptide bond. 5) Steps 2 two 4 are repeated 
until the desired peptide sequence is obtained. 6) Removal of the protection groups and 
peptide cleavage from resin.  
After the attachment of the last amino acid, all protection groups are removed and the peptide 
is cleaved from the resin. Although peptide synthesis methods are highly optimized, longer 
peptides are difficult to synthesize using SPPS, as the yield of an amino acid attachment is 
never 100%. The side products attached to the resin cumulate and as they cannot be removed, 
they can drastically affect the final yield. Also longer peptide chains start to aggregate In the 
course of the synthesis.  
O
O                    
O
O  
Figure 9. Boc (A) and Fmoc (B) protection groups. 
The most utilized protecting groups of the α-amino group are tert-butyloxycarbonyl (Boc) and 
fluorenylmethyloxycarbonyl (Fmoc) (Figure 9) [44]. Boc is acid-labile and can be removed 
with trifluoroacetic acid (TFA) [43]. Fmoc is base-labile and can be removed with piperidine 
solution in dimethylformamide (DMF) [43]. The protection groups of the N-terminus and side 
chains must be orthogonal to avoid side reactions and for that combination for example Fmoc 
and tert-butyl ester can be used [43]. As N-acylation (for the formation of peptide bond) is an 
endergonic reaction, the carboxylic group needs to be activated. Coupling reagents, which 
form anhydrides and active esters, are used as activators (Figure 10) [44].  
A B 
15 
 
N
C
+
N
N
N
N
+
OH
R
O
O
-
R O
C
+
N
O N
N
N
N
OH
N
N
N
+
O
-
R
O
R'
NH
R
O
R'NH2
++
 
Figure 10. The proposed mechanism of carboxyl group activation with 
N,N,N′,N′-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU). 
Nevertheless, SPPS does have its own shortcomings, such as large reagent consumption. The 
progression of the synthesis is difficult to observe, as the analysis of a peptide on a resin is 
complicated. Spectroscopic analyses are not as simple as in the case of liquid phase synthesis, 
because the products are not dissolved in the medium and the resin might also contribute to 
the detected signal. Chromatographic analyses are time consuming, because the product 
cleavage from the resin has to be done in advance.  
In order to verify the presence of specific functional groups simple colour tests are applied, 
such as Kaiser test, which is used for detection of primary amines and thereby monitoring the 
completeness of the reaction [45]. The test is based on the reaction of ninhydrin with primary 
amino group, which yields a characteristic blue colour [45].  
2.5.1. Aspartimide formation 
The synthesis of aspartate- or glutamate-containing peptides can be problematic as an acid- or 
base-catalysed side reaction might occur that yields in a mixture of two peptides (Figure 11) 
[44]. In strong acid the side-chain ester is protonated and vulnerable to the attack by the 
amide nitrogen, whereas in the presence of base catalysis, the amide nitrogen is deprotonated, 
which induces an attack at the side-chain carbonyl group [44]. The rearrangement occurs 
through a cyclic imide intermediate and an aspartyl residue is more affected than a glutamyl 
residue [44]. The hydrolysis of the aspartimide yields in the formation of two structural 
isomers, α and β peptide, which have identical mass. Racemization in α-carbon can also occur 
during the formation of aspartimide.  
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Figure 11. Evolvement of α and β peptides as the result of aspartimide formation. 
The formation of aspartimide can be suppressed by adding a solution of HOBt at 0.1 M 
concentration in the deprotecting solution (20% piperidine in DMF) [44]. Aspartimides also 
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form during the esterification of aspartates in a peptide. It has been shown that aspartimide 
formation during esterification can be avoided by highly optimizing the synthesis [37].  
2.6. Peptoids 
Peptoids are N-substituted glycine oligomers (NSG), which makes them structural isomers of 
peptides (Figure 12) [46]. The side chain in peptoids is attached to an amide nitrogen instead 
of the α-carbon and thus the backbone of peptoids is achiral. No hydrogen bonds can form 
between the backbones of two peptoid chains, because a tertiary amide can act as a hydrogen 
bond acceptor, but not as a hydrogen bond donor. Due to structural differences it can be 
challenging to “translate” a peptide into a peptoid. Compared to peptides NSGs have distinct 
secondary structure, which has different electronic and steric interactions [47]. Like peptides 
are peptoids capable of forming helical secondary structure, although if the side chain of a 
peptoid is achiral, the formed helix is not very stable as it interchanges between α and β helix 
conformations. Although, when a peptoid includes α-chiral side chains and some aromatic 
side chains, then the formed α-helix is even more stable than the corresponding α-helix of a 
peptide [47-49]. The peptoid concentration, solvent and temperature have much less impact 
on the stability on peptoid helicity than for peptide helicity [47].   
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Figure 12. General structures of a peptoid and a peptide. 
Peptoids have many promising therapeutic properties. NSGs are more resistant to enzymatic 
degradation as compared to α-peptides [50]. Their ability to permeate the cell membrane is 
also larger as they contain fewer hydrogen bonds and are therefore more hydrophobic [51]. 
 Peptoids can be synthesized easily with many derivatization possibilities. There are different 
kinds of methods for peptoid synthesis [46].  
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Figure 13. Monomer method of peptoids synthesis. 
The first developed method is similar to the solid phase synthesis of peptides. Previously 
prepared N-Fmoc protected N-substituted glycine monomer is activated and attached to the 
secondary amino group of a peptoid chain, which is in turn attached to a resin bead (Figure 
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13) [46]. The Fmoc group is removed and the attachment of the next monomer follows [46]. 
A disadvantage of the method is the requirement of preparing the necessary N-substituted 
glycine monomers, which are either expensive or are not commercially available. 
The most utilized synthesis method of peptoids is the submonomer method, which is based on 
alternating acylating and alkylating steps (Figure 14) [46]. An amine on a resin bead is 
acylated by an activated carboxylic acid derivative (often bromoacetic acid) [46]. During the 
acylation step the possible side-reaction is N-alkylation of resin bound amine with 
bromoacetic acid. However due to the difference in reaction rates this side reaction is 
insignificant [46]. The acylation reaction is 1000 times faster than alkylation and therefore 
only acylation is observed [46]. Acylation is followed by N-alkylation, where the halide 
(often bromide) is replaced with an amine [46]. As different primary amines have diverse 
reactivity, usually a high concentration of amine (typically 5-50 eq of amine at 0.3-2 M 
concentration) is used to guarantee the completeness of the reaction [46]. A typical cycle time 
for one monomer addition is about 150-180 minutes [46].  
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Figure 14. Submonomer method of peptoid synthesis.  
While Wang resin is one of the most utilized resins for C-terminal carboxylate peptide 
synthesis, its application in peptoid synthesis is complicated, because a diketopiperazine 
formation prevents further chain extension (Figure 15). 
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Figure 15. A diketopiperazine formation as a by-product.  
The utilization of 2-chlorotrityl chloride resin has been shown to enable the synthesis of 
peptoids containing a free C-terminal carboxylate by preventing the formation of 
diketopiperazine by steric hindrance of the trityl group (Figure 16) [52].  
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Figure 16. Structures of A) Wang resin B) 2-chlorotrityl chloride resin.  
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3. Experimental 
3.1. Reagents and equipment 
DMF was purchased from Acros Organics. Dithiothreitol (DTT), N-methylmorpholine 
(NMM), diethyl ether, bromomethyl acetate, N,N-diisopropylethylamine (DIPEA), Triton-X, 
N-Boc-1,4-butanediamine, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 
Tween 20, Pluronic F-127, DMSO, acetonitrile (ACN) were purchased from Sigma Aldrich. 
Fmoc-Gly-Wang resin, Fmoc-D-Asp(tBu)-Wang resin, 2-chlorotrityl chloride resin, HBTU 
and glycine tert-butyl ester hydrochloride were purchased from Iris Biotech. HOBt was 
purchased from Bachem. Fmoc-D-Asp(tBu)-OH and Fmoc-Sar-OH were purchased from 
NovaBiochem. Piperidine and triisopropylsilane (TIPS) were purchased from Alfa Aesar. 
Isopropanol was purchased from Rathburn. 1,2-dichloroethane (DCE), bromoacetic acid, 
triethylamine and N,N'-diisopropylcarbodiimide (DIC) were purchased from Fluka. TFA was 
purchased from Fischer Scientific. BODIPY FL C5 N-hydroxysuccinimide (NHS) ester and 
cell-lysis buffer NP40 were purchased from Invitrogen. High glucose Dulbecco’s Modified 
Eagle Medium (DMEM), Roswell park memorial institute medium (RPMI), Dulbecco’s 
Phosphate-Buffered Saline (PBS), Hank's Balanced Salt Solution (HBSS), streptomycin, 
trypsin-ethylenediaminetetraacetic acid (trypsin-EDTA) solution and penicillin were 
purchased from PAA Laboratories. Sodium chloride was purchased from Riedel-de Haën and 
trypan blue from Bio-Rad. 8-(4,5,6,7-tetrabromo-1H-benzimidazol-1-yl)octanoic acid 
(TBBi-oca), ARC-1506, ARC-1507, ARC-1508, ARC-1509, ARC-1513o were synthesized 
by Jürgen Vahter. Human cervical cancer cells (HeLa, derived from Henrietta Lacks in 1951) 
were a kind gift from Beatson Institute for Cancer Research, Glasgow. The maintenance and 
seeding of cells was performed by Darja Lavõgina. CK2α1-335 (active human recombinant) 
was a kind gift from Olaf-Georg Issinger from Institute for Biochemistry and Molecular 
Biology, University of Southern Denmark. 
Purification of the compounds was performed with Schimadzu LC Solution (Prominence) 
system by using manual injector, a diode array (SPD M20A) detector and a Shimadzu 
fluorescence detector (RF-10AXL). Separation was achieved with a Gemini C18 5 μm column 
(250×4.6 mm i.d, Phenomenex) protected by a 5 μm Gemini C18 4×2.0 mm guard column. 
The ARC-1837 decomposition experiments were performed with a Luna C18 5μm column 
(250×4.6 mm i.d, Phenomenex) protected by a 5μm Luna C18 4×3.0 mm guard column. 
Mobile phase A: 0.1 % TFA, mobile phase B: 0.1% TFA in ACN and a flow of 1 mL/min 
were employed. Linear gradient elution was started at 3 min (injection time was also at 
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3 min). Electrospray ionization mass spectrometry (ESI-MS) mass spectra were measured in 
positive ion mode on Schimadzu LCMS-2020. ESI high-resolution mass spectrometry 
(HRMS) mass spectra were measured in positive ion mode on Thermo Electron LTQ Orbitrap 
on commercial basis at the Institute of Technology (University of Tartu). ICR-HRMS mass 
spectra were measured in positive ion mode on Varian 930 FT-ICR-MS by Tõiv Haljasorg. 
Purification of the compounds with high-performance liquid chromatography (HPLC) and 
ESI-MS analysis of compounds ARC-1801, ARC-1802, ARC-1803, ARC-1804, ARC-1805 
and ARC-1806 were made by Gerda Raidaru.  
The concentrations of the ligands were determined spectrophotometrically on a Nanodrop 
2000c (Thermo Scientific) spectrophotometer. UV spectra were measured in a 2 μL volume 
with the optical path length of 0.1 cm. The following molar excitation coefficients were used: 
ε270nm(TBBi-containing compounds) = 10 000 M
-1
cm
-1
, ε505nm(ARC-1837) = 80 000, 
ε653nm(ARC-1504) = 250 000 M
-1
cm
-1
, ε653nm(ARC-1513o) = 150 000 M
-1
cm
-1
. 
Fluorescence anisotropy (FA) was measured on a PHERAstar platereader (BMG Labtech) 
with a FA optical module [ex 590 (50) nm, em 675 (50) nm] using ARC-1504 and with a FA 
optical module [ex 540 (20) nm, em 590 (20) nm] using ARC-1513o. The solutions were 
prepared on 384-well microplates with non-binding surface (Corning) using Eppendorf 
Research (Eppendorf) pipettes and 8 channel 125 μL Voyager pipette (Integra).  
Cell experiments were performed in an 8-well microscopy chamber (Ibidi). The viability of 
the cells was determined with a cell counter TC-10
TM
 (Bio-Rad). Cells were imaged with a 
microscope (TILL Photonics) using an oligochrome with xenon lamp and FITC filter [ex 475 
(35) nm, em 525 (45) nm]. Images obtained with the microscope were analysed with ImageJ 
software (version 1.47).  
Graphpad Prism software (version 5.00.288, GraphPad) and Microsoft Excel 2010 was used 
for data analysis. 
3.2. Methods 
3.2.1. Solid phase synthesis of peptides 
Peptide fragments were synthesized with traditional Fmoc SPPS method on Wang resin. After 
every amino acid attachment, an aliquot of the resin was transferred to another synthesis 
vessel to vary the number of amino acids in the conjugates. Resin (initially 58 μmol, 90.8 mg) 
was swelled for 45 minutes in DMF. Protected amino acids (3 eq) were dissolved in DMF and 
activated with a mixture of HBTU/HOBt (2.94 eq each) and NMM (9 eq) in DMF. After 
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3 minutes of preactivation, the coupling solution was added to the resin (about 1 mL/100 mg 
of resin) and shaken for 40–60 min at room temperature. The completion of each coupling 
reaction was monitored with Kaiser-test. Fmoc-group removal was performed with double 
treatment of the resin with 20% piperidine solution in DMF (5+15 min). For the synthesis of 
ARC-1818, ARC-1819, ARC-1820, Wang resin (41.6 mg, 25.0 μmol was used and the Fmoc 
removal solution contained in addition 0.1 M HOBt. After each synthetic step the resin was 
washed five times. The coupling of TBBi-oca to peptides was carried out with 1.5 eq of the 
acid activated with HOBt/HBTU (1.47 eq each) in DMF/NMM and the reaction mixture was 
shaken for at least 3h. Finally the resin was washed 5 times with each solvent (DMF, 
isopropanol, DCE) and dried in vacuum. Treatment with TFA/H2O/TIPS (90/5/5 by volume) 
for 2–3 h was used as the standard cleavage procedure. All the products were precipitated by 
the addition of 10 times excess volume of diethyl ether, pelleted by centrifugation and 
purified with HPLC using a gradient of 30%-90% ACN/30min followed by lyophilization. At 
least 300 nmol of every product was received. The structures of the compounds were 
confirmed by ESI-MS or ICR-HRMS mass-spectra (Appendices 2-12).  
3.2.2. Solid-phase synthesis of peptoids 
The peptoid parts of ligands were synthesized using a submonomer approach. After every 
monomer attachment, an aliquot of the resin was transferred to another synthesis vessel to 
vary the number of carboxylates in the conjugates. Loading (1.1 mmol/g) provided by resin 
producer was used. 2-chlorotrityl chloride resin (62.4 mg, 68.7 μmol,) was swelled for 1 hour 
in DMF. The first bromoacetic acid (5 eq) was attached to the resin dissolved in DCE with 
DIPEA (5 eq) for 2 hours at 40 °C. Washing with DCE and DMF (3 times both) followed. 
The consecutive bromoacetylations (5 eq bromoacetic acid) took place for 30 minutes in 
DMF at 40 °C with the assistance of DIC (5.5 eq).The primary amine (20 eq) was attached to 
the resin with a 2 hour reaction at 40 °C with the aid of DIPEA (20 or 40 eq). After every step 
resin was washed with DMF 5 times and the completion of every submonomer attachment 
was monitored with either chloranil test or PNBP test. The conditions of the TBBi-oca 
attachment and the cleavage of the compound were carried out as described above. All 
products were lyophilized and purified with HPLC using a gradient of 30%-90% ACN/30min. 
At least 300 nmol of every product was received. The structures of the compounds were 
confirmed with ESI-MS or ICR-HRMS (Appendices 2, 13-17, 20).  
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3.2.3. Fluorescence marker attachment 
For the synthesis of ARC-1836, a solution of BODIPY FL C5 NHS (1.5 eq) and triethylamine 
(50 eq) in DMF was added to ARC-1832. The reaction was stirred for 6 hours and then 
evaporated to dryness. The product ARC-1836 was purified with HPLC using a gradient of 
30-90% ACN/30 min and the structure was confirmed with ESI-HRMS spectra (Appendices 
2, 18).  
3.2.4. Synthesis of AM esters 
A solution of bromomethyl acetate (4.4 eq) and DIPEA (10 eq) in DMF was added to 
ARC-1836. The reaction was stirred overnight at room temperature. The product ARC-1837 
was purified by HPLC with ACN/0.1% TFA gradient 40-90% ACN/25 min and confirmed by 
ESI-HRMS (Appendices 2, 19). The rest of the chromatographic peaks were analyzed with 
ESI-MS using external calibration. Peak 1 Rt = 17.9 min, [M+H
+
]
+
 found: 1352. Peak 2 
Rt = 19.6 min, [M+H
+
]
+
: found: 1424. Peak 3 Rt = 21.3 min, [M+H
+
]
+
 found: 1497. Peak 4 
Rt = 23.0 min, [M+H
+
]
+
: found: 1568. Peak 5 Rt = 24.6 min, [M+H
+
]
+
: found: 1640. 
3.2.5. Determination of concentrations of ARC compounds 
The concentrations of the solutions of ARC-compounds were determined using UV-Vis 
spectroscopy using molar extinction coefficients derived from literature. The absorption of the 
compound was measured in reference to the solvent used for dissolving the compound.  
The concentration of the compound was calculated using Lambert-Beer law (Equation 1).  
      
Equation 1. Lambert-Beer law. A – absorption, ε – molar extinction coefficient,                       
c – concentration, l – path length.  
3.2.6. Fluorescence anisotropy assay 
Fluorescence anisotropy assays were performed in the assay buffer (50 mM HEPES pH=7.5, 
150 mM NaCl, 0.005% Tween 20, 5 mM DTT) with a final volume of 20 μL. Microplates 
were incubated for 10 or 20 minutes at 30 °C before the measurement.  
A binding assay was used to determine the active concentration of CK2α1-335 by titrating the 
kinase with ARC-1504 [38]. A dilution series of CK2α1-335 starting from 200 nM (2-fold 
dilutions) was prepared and ARC-1504 was added to each well at fixed concentration (final 
total concentration of 10 nM). After the incubation, the values of fluorescence anisotropy 
were measured using 10 nM ARC-1504 solution without the kinase to calibrate the detector. 
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A graph was constructed with the kinase concentration on the horizontal axis and the 
anisotropy value on the vertical axis. The active concentration of CK2α1-335 was calculated 
using non-linear regression analysis (Equation 2) [31]. 
  
         √                 
   
 
  
  
        
 
              
Equation 2. k – active/total kinase concentration, Y – measured anisotropy value,                 
KD – dissociation constant of the kinase and the ligand, Lt – total concentration of the ligand,  
x – total concentration of the kinase, Q – ratio of fluorescence intensities of bound and free 
ligand, Ab – anisotropy of completely bound ligand, Af – anisotropy of the free ligand.  
A displacement assay was used to determine the binding affinities of ligands. Fixed 
concentration of the fluorescent probe ARC-1504 (2 or 3 nM) or ARC-1513o (1 nM) in 
complex with the kinase CK2α1-335 (3 or 2 nM) was added to each well of the concentration 
series of competing compound under interest (3 fold dilutions starting from 100, 10 or 1 μM). 
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Equation 3. Af – anisotropy of free fluorescence ligand; Ab – anisotropy of the complex;       
Lt – total concentration of the fluorescence ligand; Rt – total concentration of the active 
kinase; Kd1 – dissociation constant between the fluorescence ligand and the kinase;              
Kd2 – dissociation constant between the competing ligand and the kinase; x – logarithm of the 
total concentration of the competing ligand; Y – measured anisotropy value.  
A solution with no inhibitor was prepared as the maximum reference value.  After the 
incubation, the values of fluorescence anisotropy were measured using a 10 nM ARC-1504 
solution without the kinase to calibrate the detector. The fluorescence anisotropy values were 
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analysed using exact competitive binding model (Equation 3) [31]. The anisotropy change is 
presented in reference to the solution containing no kinase. At least three parallel 
measurements were performed with freshly prepared solutions on different days.  
3.2.7. Monitoring ARC-1837 decomposition 
The qualitative analysis of the ARC-1837 decomposition in live cells and in buffer was 
determined with HPLC using a gradient of 30%-90% ACN/30min.  
An HPLC analysis was conducted using DMSO solution of ARC-1837 (concentration of 
2.1 mM) that had been stored at -20 °C for 1 month. A solution of ARC-1837 (10 μM) was 
made from the same stock solution in the buffer (50 mM HEPES pH=7.5, 150 mM NaCl, 
0.005% Tween 20, 0.1% Pluronic F-127) and incubated at 37 °C for 24 hours. The hydrolysis 
reaction was monitored with HPLC at fixed time points (1.5; 3; 24 h). To determine the mass 
spectra of the decomposition products, ARC-1837 was dissolved in 50:50 DMSO:buffer 
(50 mM HEPES pH=7.5, 150 mM NaCl, 0.005% Tween 20) solution and incubated at 70 °C 
for 4 hours (Appendix 21). Non-decomposed ARC-1837 was used as an internal standard 
prior to HPLC analysis.  
For intracellular decomposition analysis, cells were seeded on a 6-well culture plates at an 
initial density of 300 000 cells per well. Cells were grown in the medium (DMEM 
supplemented with 10% FBS, 100 U/mL penicillin, 100 μg/mL streptomycin) and maintained 
at 37 °C in a humidified 5% CO2 environment for 2 days. After two days, the medium was 
removed and cells were washed with PBS twice. 10 μM ARC-1837 solution was prepared in 
serum- and antibiotics-free DMEM medium (500 μL) containing 1% DMSO and 0.1% 
Pluronic F-127. A control solution containing the same components but no ARC-1837 was 
also prepared. The solutions were added to cells and incubated for 1 h at 37 °C in humidified 
5% CO2 environment. Next, the solutions were removed and cells were washed twice with 
PBS. To cleave the proteins that bind cells to the plate, 400 μL of 0.25% trypsin-EDTA 
solution in PBS was added to both wells and the cells were incubated for 3 minutes. 3 mL of 
medium containing serum was used to wash cells off the plate surface and the suspensions 
were transferred to plastic tubes. The suspensions were centrifuged for 5 minutes at 100 g and 
the supernatants were removed. 1 mL of PBS was added to the pellets to wash the cells and 
the suspensions were centrifuged again with the same conditions. Next, the supernatants were 
removed and cells were thoroughly re-suspended with 1 mL of PBS. 15 μL of both cell 
suspensions were taken for cell viability experiments. The rest of the cell suspensions (each 
ca 985 μL) were centrifuged at 100 g for 5 minutes, the supernatants were removed and the 
24 
 
pellets were re-suspended in 200 μL of cell lysis buffer with 1% Triton-X. Cells were lysed 
on ice for 30 minutes with mixing after every 10 minutes. For protein precipitation, 400 μL of 
ACN was added to both of the samples and the solutions were mixed for 3 minutes. Next, the 
solutions were centrifuged at 20 000 g for 30 min. After that the supernatants were collected 
and dried in a rotational vacuum-concentrator. Dry samples were suspended in 30 μL of 
ACN:DMSO solution (1:1) and centrifuged at 10 000 g. The supernatants were used for 
HPLC analysis using a gradient of 30%-90% ACN/30min and a fluorescence detector. 
3.2.8. Cell viability 
To determine the viability of the cells, 15 μL of the cell suspension was taken and mixed with 
0.4% trypan blue solution [53]. 10 μL of the obtained solution was added to both chambers of 
the counting slide and the viability was measured with the cell counting instrument three 
times for both of the chambers.  
3.2.9. Microscopy analysis 
For live cell imaging 20 000 cells were seeded on an 8-well microscopy chamber and grown 
as described above. After 1-2 days of maintenance, the medium was removed and the cells 
were incubated with the solutions of ARC-compounds (10 μM and 1 μM, total 200 μL) in 
serum- and antibiotics-free medium containing 1% DMSO and 0.1% Pluronic F-127 for 1 or 
2 hours. After the incubation, the solutions were removed and the cells were washed 2 times 
with PBS buffer and once with indicator-free RPMI buffer (prolonged wash). During the 
microscopy analysis, cells were kept in 200 μL of HBSS buffer at room temperature. 
Oligochrome was used as the light source [150 W Xenon high stability lamp, excitation filter 
475 (35) nm, emission filter 525 (45) nm]. The experiments were performed at 50 ms 
exposure time. 20% and 50% of the maximal power of the lamp was used observing 
compounds ARC-1837 and ARC-1836, respectively. 20x oil objective was used for imaging. 
The intensities of the images were auto-scaled. Obtained images were analysed and modified 
(colour adjustment with a 40% increase in intensity and contrast) with ImageJ.  
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4. Results and discussion 
During the previous studies, a highly affine compound ARC-1504 that contains five aspartate 
residues has been developed as selective probe towards CK2 (Appendix 22) [33]. 
Unfortunately, unlike oligoarginine-containing ARC-s, ARC-1504 is strongly negatively 
charged at physiological pH and does not have the intrinsic property to cross the plasma 
membrane. A common approach for the introduction of negatively charged molecules inside 
the cells is the esterification of carboxylic groups with AM esters [36-41]. The purpose of this 
thesis was to apply this approach on an inhibitor for CK2 containing an oligoaspartate. 
The peptide part of ARC-1504 had not been optimized previously and therefore the first step 
was to examine how the number of aspartates influences the affinity of a compound and 
whether it would be possible to decrease this number in order to reduce the structural 
complexity. As ARC-1504 contains mainly L-amino acids, it was also necessary to assess 
how chirality affects binding.   
A series of conjugates containing 1-7 D-Asp residues was synthesized according to the 
published procedures by Fmoc peptide synthesis methods on Wang resin (Appendix 1) 
[42, 43]. All the compounds were purified with HPLC and analysed with ESI-MS or ICR-
HRMS.  
Compounds containing TBBi can be easily identified, as natural bromine consists of two 
stabile isotopes (78.918338 50.69%; 80.916291 49.31%) [54]. Therefore, compounds 
containing four bromine atoms have a characteristic MS spectrum (Figure 17). 
                
Figure 17. Calculated mass-spectra of protonated TBBi [55]. 
Purification of compounds containing 4 to 7 aspartate residues (ARC-1804, ARC-1805, 
ARC-1806 and ARC-1807) resulted in two isomers (marked as I and II), which could be 
separately collected. The two isomers of ARC-1807 were inseparable and were therefore 
collected as a mixture. Most probably, the two isomers were α and β peptides due to 
aspartimide formation in the sequence Asp(OR)-Gly, because this sequence is particularly 
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prone to the formation of aspartimide [44]. As the synthesis of all the conjugates was carried 
out in a single vessel by taking an aliquot after every amino acid attachment, the aspartimide 
formation during the fourth amino acid attachment was ‘carried over’ to all the consecutive 
synthesized compounds resulting in formation of two isomers for every compound. Because it 
is very difficult to determine the structures of the two isomers, the syntheses of compounds 
containing 4, 5 and 6 aspartates were repeated. This time during every N-terminal 
deprotection 0.1 M HOBt solution was added to the reaction medium, because this approach 
is reported to depress the formation of aspartimide; also a resin without previously attached 
Gly was used [44]. All the compounds were purified with HPLC and analysed with ESI-MS 
or ICR-HRMS. The chromatograms revealed only one peak with the correct m/z for every 
synthesis revealing no aspartimide formation had occurred.  
The affinities of synthesized inhibitors were measured with fluorescence anisotropy assay. 
The concentration of the active kinase was determined with a fluorescence anisotropy-based 
binding assay before every displacement assay. The content of active CK2α1-335 was usually 
around 20-30% (Figure 18A). In this study, a CK2α1-335 C-terminal deletion mutant 
comprising amino acids 1-335 was used, because it is more stable as compared to full length 
human CK2α(1-391) [56]. When excited with polarized light, kinase-bound portion of 
ARC-1504 (KD = 0.4 nM, labelled with fluorescence dye PromoFluor 647, ex/em maximum: 
654/672 nm) emits polarized light after excitation [33]. When the fluorescent probe in an 
unbound state is excited with the polarized light, it emits depolarized light.  
 
0 50 100 150 200 250
0
50
100
150
nominal  C (CK21-335), nM

r

 1
0
0
0
-11 -10 -9 -8 -7 -6 -5 -4
0
50
100
150 ARC-1801
ARC-1802
ARC-1803
ARC-1818
ARC-1819
ARC-1820
     [E] = 0[I] = 0
log(C/M)

r

 1
0
0
0
 
Figure 18. A) Titration of 10 nM ARC-1504 with CK2α1-335 B) Displacement curves of 
non-labelled compounds using ARC-1504 (2 nM with ARC-1801, ARC-1802; 3 nM with the 
rest) as competitive probe and CK2α1-335 (3 nM with ARC-1801, ARC-1802; 2 nM with the 
rest).  
The affinities of compounds were measured with the displacement assay based on 
fluorescence anisotropy measurements (Figure 18B, Appendix 23, Table 1). ARC-1504 was 
used for the affinity measurements of compounds containing 1-6 aspartate residues. As 
A) B) 
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determination of the affinities of unlabeled compounds is limited by the Kd value of the 
fluorescent ligand, more affine fluorescent probe ARC-1513o (KD = 0.01 nM) was used for 
assaying compounds containing 6-7 aspartate residues (Appendix 22) [57, 58]. 
Table 1. Affinities of different ARC-type inhibitors determined by the displacement assay. 
Number of 
aspartates 
Compounds containing D-Aspartates Compounds containing L-Aspartates 
Compound code Kd (SD), nM Compound code Kd (SD), nM 
1 ARC-1801 45.2 (3.1) ARC-1506 43.4 (6.9) 
2 ARC-1802 18.5 (7.5) ARC-1507 26.8 (8.2) 
3 ARC-1803 4.03 (0.18) ARC-1508 4.64 (3.15) 
4 ARC-1804 I 2.20 (0.51) 
ARC-1518 2.21 (0.20) 
ARC-1804 II 1.43 (0.37) 
ARC-1818 1.56 (0.60) 
5 ARC-1805 I 0.86 (0.36) 
ARC-1519 1.72 (1.09) 
ARC-1805 II 0.63 (0.23) 
ARC-1819 0.80 (0.36) 
6 ARC-1806 I 0.52 (0.24) 
ARC-1509 0.55 (0.40) 
ARC-1806 II 0.39 (0.23) 
ARC-1820 0.52 (0.38) 
7 ARC-1807 I-II 0.25 (0.12) n.d. 
The measured affinities of the isomers (I and II) did not differ from each other significantly, 
indicating that the position of the carboxylate can be altered without having an effect on the 
affinity of the compound (Table 1, Figure 19).  
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Figure 19. Comparison of the affinities of collected isomers. 
According to these results, every additional aspartate residue increased the affinity about 2-3 
times (Table 1). A plateau of saturation of affinity was not achieved within this series of 
compounds and it could be hypothesized that adding subsequent residues would increase the 
affinity even more. It was also clear that the affinity of a compound could be easily regulated 
by varying a number of aspartates. For example, attachment of three carboxylic groups to 
TBBi via an adequate linker yields in a 100-fold increase in affinity. The comparison of the 
compounds containing either D- or L-aspartate residues revealed that the affinities of the 
conjugates were statistically indistinguishable. These results in combination with the 
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previously reported crystallographic evidence imply that no fixed interactions are formed 
between the negative charges of the conjugate and the kinase [33].  
Previously, it has been demonstrated that the transformation of carboxylic acids to AM esters 
in peptides is complicated as the esters are not stable and form aspartimides very easily [59]. 
There are a few examples, where a cyclic peptide has been esterified, but with highly 
optimized reaction conditions [37]. As the present work indicated that chirality of inhibitor 
does not affect affinity in case of CK2 and the peptide fragment can be flexible, it was 
decided to synthesize compounds incorporating achiral isomers of peptides called peptoids, 
which are incapable of forming aspartimides. 
Eight peptoids containing different number of Nasp groups were synthesized (Figure 20, 
Appendix 1). N-4-aminobutylglycine (Nlys) was added to C-terminals of peptoids to enable 
the subsequent dye attachment. Previously it has been shown that additional negative charge 
in the C-terminus of the peptide part has positive effect on the affinity of the compounds [59]. 
For peptoid synthesis, 2-chlorotrityl chloride resin was used, which enables to synthesize 
peptoids containing a free C-terminal carboxylate [52]. Tert-butyl ester was used as the 
protection group of the side chains. The progression of the synthesis was monitored with 
PNBP and chloranil tests [60, 61]. During the synthesis of ARC-1839, the second 
N-carboxymethylglycine (Nasp) was replaced with N-methylglycine (Nala) to assess the 
influence of the second Nasp on the affinity. Nala was added in the form of Fmoc-sarcosine. 
Finally, TBBi-oca was attached to the peptoid; the product was cleaved from the resin and 
purified with HPLC. Every additional carboxylate residue increased hydrophilicity of the 
compound and therefore decreased the retention time in the HPLC analysis. ESI-MS and 
ICR-HRMS analyses determined a good agreement between theoretical and measured mass 
spectra. 
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Figure 20. General structure of synthesized peptoids. n = 2…6. 
The syntheses of peptides and peptoids are similar in a way that one monomer attachment 
needs two steps to be completed. An attachment of one amino acid to a peptide chain takes 
about 2 hours. One monomer attachment in peptoid synthesis takes about 4 hours. When 
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comparing the time-scale of peptide and peptoid synthesis, the latter one is more 
time-consuming.  
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Figure 21. Displacement curves of non-labelled compounds using ARC-1504 (2 nM) as 
competitive probe and CK2α1-335 (3 nM). 
The affinities of peptoids were measured with the displacement assay using ARC-1504 as the 
fluorescence ligand (Figure 21, Table 2).  
Table 2. Structures, codes and affinities of synthesized peptoids. n.d. – not determined.  
Inhibitor structure Compound code Kd (SD), nM 
TBBi-oca-(Nasp)2-Nlys-OH ARC-1831 131 (52) 
TBBi-oca-(Nasp)3-Nlys-OH ARC-1832 33.3 (2.2) 
TBBi-oca-(Nasp)4-Nlys-OH ARC-1833 10.2 (2.2) 
TBBi-oca-(Nasp)5-Nlys-OH ARC-1834 3.34 (0.65) 
TBBi-oca-(Nasp)6-Nlys-OH ARC-1835 2.18 (1.37) 
TBBi-oca-(Nasp)3-(Nlys-BODIPY FL)-OH ARC-1836 21.5 (2.0) 
TBBi-oca-(Nasp-AM)3-(Nlys-BODIPY FL)-AM ARC-1837 n.d. 
TBBi-oca-Nasp-Nala-Nasp-Nlys-OH ARC-1839 95 (25) 
As expected, the affinities increased with the increasing number of Nasp. Yet the measured Kd 
values were about five times higher than dissociation constants of peptides containing the 
same number of carboxylates in side chains (Figure 22). This could be caused by positively 
charged ammonium group in Nlys subunit, which might affect binding negatively as has been 
reported previously [34]. The Kd value of ARC-1839 (containing 2 Nasp, 1 Nala residues and 
the C-terminal carboxylate) revealed that the second Nasp influences the affinity notably as 
the Kd value increased about three times when this Nasp was replaced with Nala. These 
results provide further supporting info that the peptide binding cleft of protein kinase CK2 is 
not very sensitive to the exact positions of negative charges in the structure of inhibitors, but 
rather to the overall charge. 
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Figure 22. Affinity comparison between synthesized peptides and peptoids. 
Compounds containing several carboxylates cannot penetrate a cell membrane because of the 
large overall negative charge. For the cell experiments the carboxyl groups were masked with 
AM esters. As AM esters are not very stable, it was reasonable to reduce the number of esters 
to minimum. Yet, the abundance of carboxylates was essential as every additional carboxylate 
increased the affinity of a compound. In this study a peptoid with three carboxyl side groups 
was chosen for the pilot test. For the esterification, the compound ARC-1836 was reacted 
with bromomethyl acetate in DMF in the presence of base overnight. The chromatographic 
analysis of the synthesis revealed five separate peaks with MS spectra that corresponded to 
compounds with different number AM ester groups, which means that the reaction did not 
proceed to the end at conditions described above and needs to be optimized. The product 
(ARC-1837) peak was collected and analysed with HRMS that confirmed the agreement of 
the theoretical and measured MS spectra. The Kd value of ARC-1837 decreased compared to 
the affinity of unesterified compound ARC-1836, which supports the idea that elimination of 
the positive charge near the C-terminus increases the affinity of the compound. 
In order to make the compound visible inside a cell, a fluorescence dye BODIPY FL C5 was 
attached to the inhibitor. BODIPY FL was chosen because of its excellent optical properties, 
lack of overall charge and small size. The synthesis took place in DMF with triethylamine for 
6 hours. HPLC analysis revealed one major peak and HRMS analysis confirmed a good 
agreement between theoretical and measured mass spectra.  
As AM esters are known to be prone to hydrolysis, the hydrolytic stability of ARC-1837 was 
examined with HPLC (Figure 23) [40]. About 6% of ARC-1837 was decomposed when 
stored in DMSO solution at 2.1 mM concentration for one month at -20 °C as revealed by 
HPLC analysis. The chromatogram after 1.5 hour incubation in assay buffer revealed that the 
initial esterified compound ARC-1837 had hydrolysed further. The peak corresponding to 
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ARC-1837 covered about 82% of the total peak area after 1.5 hours and about 80% after three 
hours. 
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Figure 23. Hydrolysis of ARC-1837 at 37 °C in buffer (pH = 7.5, A) and in cell (1 h, A and 
B). Chromatograms are normalized according to the peak with the highest intensity. 
After incubation in buffer for 24 hours, the fully esterified compound was almost completely 
decomposed as the peak corresponding to non-decomposed ARC-1837 covered only about 
6% of the total peak area, although there were present several intermediate compounds in 
considerable amounts. To verify that those five peaks correspond to compounds differing in 
the number of ester groups, as it was observed in the purification of the reaction mixture of 
the esterification, attempts to measure ESI-MS spectra were made. Unfortunately the signals 
of the compounds were not high enough for acceptable signal-to-noise ratio in ESI-MS 
measurement, possibly due to the presence of detergents. To determine the m/z of the 
decomposition products, the hydrolysis was repeated using a 1 mM solution of ARC-1837 in 
a 50:50 mixture of DMSO and buffer (without detergent) as the solvent for proper dissolution 
of ARC-1837 and incubating at 70 °C for 4 hours. Before the HPLC-MS analysis, some 
non-decomposed ARC-1837 was added to the hydrolysis solution to assure the presence of all 
the compounds differing in number of ester groups. The retention times of the products from 
the latter hydrolysis match to the retention times of the products from the first hydrolysis 
experiment. An external calibration was used (chromatogram and ESI-MS spectra prior to the 
calibration are present in Appendix 21). The mass spectra of the peaks that appear as the 
result of decomposition indeed match to the mass-spectra of compounds lacking one, two, 
three or four AM ester groups (Table 3).  
 
 
B) A) 
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Table 3. Mass-spectra of decomposition products compared with theoretical spectra. 
Peak Retention 
time (min) 
ESI-MS [M+H
+
]
+
 (achieved with 
external calibration) 
Calculated base peak 
[M+H
+
]
+
 
1 23.2 1352 ARC-1836: 1352.1137 
2 25.5 1424 ARC-1837 – 3 AM ester: 
1424.5478 
3 27.6 1496 ARC-1837 – 2 AM ester: 
1496.6105 
4 29.6 1569 ARC-1837 – 1 AM ester: 
1568.6733 
5 31.5 1640 ARC-1837: 1640.1982 
Next, compound ARC-1837 was applied in cell experiments to test the cellular uptake of the 
compound. Most of the earlier cellular experiments with ARC-compounds and compounds 
containing AM-esters have used up to a 10 μM solution and an incubation time of 1 hour, 
therefore similar conditions were applied [29, 62]. The experiments were carried out at 1 and 
10 μM concentrations of fluorescent compounds using HeLa cells and with 1 and 2 hour 
incubation periods. As a reference, cells were also incubated with unesterified compound 
ARC-1836. The localization of the fluorescent compound inside the cells can be seen from 
the obtained microscopy images (Appendix 24). The compound ARC-1837 is distributed in 
the cytoplasm in every cell, while the cell nuclei are less stained. The latter observation is 
dramatically different from the previous studies with arginine-rich ARCs which stained 
intensely speckles in the cell nuclei (probably due to interaction with negatively charged 
DNA or RNA present in the nucleus). Therefore, nuclear exclusion serves as an indirect 
evidence for the fact that carboxylate-rich ARCs possess reduced non-specific binding to 
nucleic acids. However, it should be noted that for CK2 itself, both cytoplasmic and nuclear 
localization has been reported [21]. Still, it is possible that inhibition of CK2 might have 
promoted its transport out of the nucleus, which remains to be established in future 
experiments. 
ARC-1837 also stained more intensely some bright spots near cell nuclei, which could 
represent microtubule-rich area near the centrosome (in interphase, centrosome(s) are attached 
to the nuclear membrane); importantly, centrosomal enrichment of CK2 has also been 
previously reported [62]. Further studies (e.g., cross-staining of well-established centrosomal 
components) will be required to confirm this notion. Interestingly, in case of increased cell 
confluence, intense staining of the cell plasma membrane by ARC-1837 was also evident; 
however, this might have been caused by non-specific binding of relatively hydrophobic 
BODIPY moiety to the membrane regions with increased thickness. A compound with a 
different fluorescent label could be synthesized to test this hypothesis.  
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Compound ARC-1836 (without AM esters) has poorly entered the cells and does not have a 
diffuse distribution. In contrast to ARC-1837, the non-esterified ARC-1836 possessed 
strongly endosomal staining pattern. During the observation of the cell membrane-permeation 
of ARC-1836, the required intensity of the light source for a decent signal to noise ratio was 
2.5 times higher than for ARC-1837 due to weaker fluorescence signal of the former 
compound. Overall, it was confirmed that introduction of AM esters strongly facilitates the 
uptake of carboxylate-rich compounds in the cells, and results in profoundly changed staining 
profile (i.e., as compared to the non-esterified compound). 
Determination of the viability of the cells after treatment with an inhibitor is essential, if the 
probe is used as a tool for studying cellular processes. For cell viability experiments HeLa 
cells were incubated with 10 μM ARC-1837 for 1 hour and the viability was measured with a 
cell counter using instructions provided from the manufacturer [53]. For comparison cells 
were also incubated with a solution that did not include ARC-1837. The proportion of live 
cells over total cells was 88% (SD 3%) when incubated with medium containing ARC-1837 
and 82% (SD 8%) when incubated without ARC-1837. These results indicate that during the 
incubation period of 1 hour the cell viability is not affected by the presence of ARC-1837. 
For the effective binding between the inhibitor and CK2, the ester groups of ARC-1837 need 
to be hydrolysed. The chromatographic analysis of intracellular stability of ARC-1837 
revealed a dominating peak, which corresponded to the completely hydrolysed compound 
ARC-1836 (Figure 23). In addition, there was a smaller peak with Rf value of 31.7 min, which 
corresponded to the Rf value of the initial compound ARC-1837. Between these peaks, there 
were three small peaks with Rf values equal to the Rf values of previously determined 
hydrolysis products, which indicated with high probability that most of the AM ester groups 
of ARC-1837 had been hydrolysed. As ARC-1837 was used in cell experiments within 
maximally 2.5 hours, the decomposition of ester groups in such short time-scale could not be 
attributed to hydrolysis initiated by water only, but also by intracellular esterases. Yet, 
hydrolysis of all ester groups was incomplete, which has also been reported previously for 
AM esters of calcium sensors [64].  
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Summary 
The purpose of this study was to develop a cell membrane permeable inhibitor for CK2. To 
accomplish this goal, it was initially necessary to establish how the affinities of ARC-type 
compounds depend on the chirality and on the number of amino acids. For that reason, 
7 inhibitors containing different number of D-Aspartate residues were synthesized. Their 
affinities were measured and compared to affinities of inhibitors containing the same number 
of L-Aspartate residues synthesized by Jürgen Vahter. The binding experiments revealed that 
the affinity did not depend considerably on chirality and that the Kd values of the synthesized 
inhibitors decreased about three times with every additional aspartate residue.  
As an aspartate residue is negatively charged in a physiological environment, compounds 
containing several aspartates are incapable of permeation the cell membrane. Utilization of 
prodrug approach with AM esters to mask negatively charged groups is a possible way to 
overcome the problem. After the compound crosses the plasma membrane, intracellular 
esterases cleave the esters to release the original compound. As peptides containing AM esters 
are generally unstable and form aspartimides very easily, peptide isomers called peptoids can 
be used instead. Five peptoids containing different number of Nasp monomers were 
synthesized and their affinities were measured in biochemical assay with CK2. A peptoid 
containing three Nasp monomers with a Kd value of 33.3 nM was chosen for cell experiments. 
A fluorescent dye was attached to the peptoid and its carboxylates were esterified.  
The acquired esterified compound ARC-1837 but also the unesterified compound ARC-1836 
were applied to cell experiments. Microscopy analyses verified that ARC-1837 permeated the 
cell membrane much more easily than ARC-1836. Hydrolysis experiments in buffer were 
conducted to examine the stability of AM esters in aqueous environment. The compound was 
quite stable over the time range that was used in cell experiments. The intracellular stability of 
ARC-1837 was examined and the results showed that after 1 h incubation in cell, the initially 
esterified compound ARC-1837 had lost most of its ester groups. It can be hence concluded 
that the AM esters are efficiently cleaved by intracellular esterases. 
To sum up, in this work a new cell membrane-permeable esterase-activated inhibitor of CK2 
was designed and synthesized. It was demonstrated that the compound possessed low 
nanomolar affinity in the biochemical studies, permeated the cell membrane and was activated 
by intracellular esterases.  
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Proteiinkinaasi CK2 polüanioonsete inhibiitorite derivatiseerimine nende 
efektiivseks transpordiks rakkudesse 
Siiri Saaver 
Kokkuvõte 
CK2 on kinaas, mis osaleb väga paljudes rakuprotsessides. Tema liigset aktiivsust rakus 
seostatakse erinevate haigustega, mistõttu on CK2 saanud üheks ravimitööstuse sihtmärgiks. 
Varasemalt on Asko Uri uurimisrühmas arendatud CK2 jaoks kõrgafiinseid ja selektiivseid 
inhibiitoreid, kuid need on negatiivselt laetud ja seetõttu rakumembraani edukalt läbida ei 
suuda. Atsetoksümetüülestritega on võimalik negatiivsed laengud maskeerida rakumembraani 
läbimise ajaks ning rakus hüdrolüüsitakse ühend esteraaskatalüütiliselt algseks laengutega 
konjugaadiks. 
Käesoleva töö eesmärgiks oli välja arendada ARC-tüüpi rakkusisenev inhibiitor 
proteiinkinaasi CK2 jaoks. Esmalt uuriti asparagiinhapete arvu ja kiraalsuse mõju inhiibitori 
afiinsusele. Selle jaoks sünteesiti seitse TBBi-oligoaspartaadi konjugaati, mis sisaldasid 1-7 
D-asparagiinhappe jääki. Saadud ainete võimet seonduda proteiinkinaasiga CK2 võrreldi 
Jürgen Vahteri poolt sünteesitud L-asparagiinhappe jääke sisaldavate ühendite afiinsustega. 
Selgus, et ühendite dissotsiatsiooni-konstandid ei sõltu märgatavalt neis sisalduvate 
aminohapete kiraalsusest. See-eest afiinsus kasvas märgatavalt iga lisatud asparagiinhappega. 
Kuna atsetoksümetüülestreid sisaldavad peptiidid on väga ebastabiilsed ning moodustavad 
kergesti aspartimiide, on võimalik kasutada peptoide peptiidide asemel. Sünteesiti viis 
peptoidi, mis sisaldasid erineva arvu karboksüülrühmi sisaldavaid külgahelaid. Saadud 
ühendite afiinsused mõõdeti ning edasisteks eksperimentideks valiti konjugaat, mis sisaldas 
nelja karboksüülrühma. Valitud ühendile kinnitati fluorestsentsvärv ning ühendist valmistati 
atsetoksümetüülester.  
Näidati, et saadud TBBi-peptoidkonjugaat siseneb AM estri vormis efektiivselt rakku ning 
hüdrolüüsitakse rakusiseselt lähteühendiks.  
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Appendix 1. Structures and codes of synthesized ARC-type inhibitors. 
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Appendix 2. MS analyses of synthesized ARC-compounds.  
ARC-code Compound Calculated base peak [M+H
+
]
+
 Rt (min) ESI-MS  
ARC-1801 TBBi-oca-(D-Asp)-Gly-OH 749 18.2 749 
ARC-1802 TBBi-oca-(D-Asp)2-Gly-OH 864 17.0 864 
ARC-1804 TBBi-oca-(D-Asp)4-Gly-OH 1094 I 15.6 
II 15.9 
I 1094 
II 1094 
ARC-1805 TBBi-oca-(D-Asp)5-Gly-OH 1209 I 14.8 
II 15.1 
I 1209 
II 1209 
ARC-1806 TBBi-oca-(D-Asp)6-Gly-OH 1324 I 14.4 
II 14.6 
I 1324 
II 1324 
ARC-1807 TBBi-oca-(D-Asp)7-Gly-OH 1440 I 14.4 
II 14.5 
I 1440 
II 1440 
ARC-1819 TBBi-oca-(D-Asp)5-OH 1152 15.7 1152 
ARC-1820 TBBi-oca-(D-Asp)6-OH  1267 15.4 1267 
ARC-1832 TBBi-oca-(Nasp)3-Nlys-OH 1050 13.3 1050 
ARC-1833 TBBi-oca-(Nasp)4-Nlys-OH 1165 13.0 1165 
ARC-1834 TBBi-oca-(Nasp)5-Nlys-OH 1281 12.9 1281 
ARC-1835 TBBi-oca-(Nasp)6-Nlys-OH 1396 12.8 1396 
 
 
 
ARC-code Compound Calculated monoisotopic mass [M+H
+
]
+
  Rt (min) ICR-HRMS ESI-HRMS 
ARC-1803 TBBi-oca-(D-Asp)3-Gly-OH 974.90464 15.8 974.90422 n.d. 
ARC-1818 TBBi-oca-(D-Asp)4-OH 1032.91012 16.1 1032.91000 n.d. 
ARC-1831 TBBi-oca-(Nasp)2-Nlys-OH 930.95120 13.7 930.94977 n.d. 
ARC-1836 TBBi-oca-(Nasp)3-(Nlys-BODIPY FL)-OH 1348.1178 22.5 n.d. 1348.1191 
ARC-1837 TBBi-oca-(Nasp-AM)3-(Nlys-BODIPY FL)-AM 1636.2023 24.7 n.d. 1636.2044 
ARC-1839 TBBi-oca-Nasp-Nala-Nasp-Nlys-OH 1001.98831 13.3 1001.98805 n.d. 
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Appendix 3. ARC-1801. A) Chromatogram of the purification B) ESI-MS spectrum.  
 
 
 
 
  
A) 
B) 
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Appendix 4. ARC-1802. A) Chromatogram of the purification B) ESI-MS spectrum. 
 
 
 
  
A) 
B) 
49 
 
Appendix 5. ARC-1803. A) Chromatogram of the purification B) ICR-HRMS on the next 
page. 
A)
 
  
50 
 
  
B
) 
51 
 
Appendix 6. ARC-1804 A) Chromatogram of the purification B) ESI-MS spectrum of the I 
fraction C) ESI-MS spectrum of the II fraction. 
 
 
 
 
 
 
 
  
B) 
A) 
C) 
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Appendix 7. ARC-1805. A) Chromatogram of the purification B) ESI-MS spectrum of the I 
fraction C) ESI-MS spectrum of the II fraction.  
 
 
 
 
 
 
  
A) 
B) 
C) 
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Appendix 8. ARC-1806. A) Chromatogram of the purification B) ESI-MS spectrum of the I 
fraction C) ESI-MS spectrum of the II fraction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B) 
A) 
C) 
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Appendix 9. ARC-1807. A) Chromatogram of the purification B) ESI-MS spectrum of the I 
fraction. C) ESI-MS spectrum of the II fraction. 
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A) 
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Appendix 10. ARC-1818. A) Chromatogram of the purification B) ICR-HRMS spectrum on 
the next page. 
A) 
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Appendix 11. ARC-1819 A) Chromatogram of the purification B) ESI-MS spectrum. 
 
 
  
A) 
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Appendix 12. ARC-1820 A) Chromatogram of the purification B) ESI-MS spectrum. 
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Appendix 13. ARC-1831 A) Chromatogram of the purification B) ICR-HRMS spectrum on 
the next page. 
A)
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Appendix 14. ARC-1832 A) Chromatogram of the purification B) ESI-MS spectrum. 
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Appendix 15. ARC-1833 A) Chromatogram of the purification B) ESI-MS spectrum. 
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Appendix 16. ARC-1834 A) Chromatogram of the purification B) ESI-MS spectrum. 
A) 
 
B) 
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Appendix 17. ARC-1835 A) Chromatogram of the purification B) ESI-MS spectrum. 
A) 
 
B) 
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Appendix 18. ARC-1836 A) Chromatogram at 260 nm detector wavelength B) 
Chromatogram at 505 nm detector wavelength C) HRMS spectra. 
A) 
 
 
B) 
 
 
C) 
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Appendix 19. ARC-1837 A) Chromatogram of the purification at 260 nm detector 
wavelength B) Chromatogram of the purification at 505 nm detector wavelength C) HRMS 
spectrum. 
A) 
 
B) 
 
 
 
 
 
 
C) 
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Appendix 20. ARC-1839 A) Chromatogram of the purification at 260 nm detector 
wavelength B) ICR-HRMS spectrum on the next page. 
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Appendix 21. Chromatogram of the hydrolysis solution and MS spectra of every 
chromatographic peak (continues on the next page). 
Chromatogram 
 
MS spectrum at 23.2 min 
 
MS spectrum at 25.5 min 
 
MS spectrum at 27.6 min 
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MS spectrum at 29.6 min 
 
MS spectrum at 31.5 min 
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Appendix 22. Structures of ARC-1513o (A) and ARC-1504 (B). 
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Appendix 23. Measured pIC50 values of inhibitors. 
 
 
 
 
 
 
 
 
  
Compound pIC50 (SE) 
ARC-1801 -6.47 (0.03) 
ARC-1802 -6.95 (0.03) 
ARC-1803 -7.26 (0.10) 
ARC-1818 -7.99 (0.03) 
ARC-1819 -8.73 (0.10) 
ARC-1820 -8.63 (0.06) 
ARC-1831 -6.02 (0.05) 
ARC-1832 -6.58 (0.02) 
ARC-1833 -7.09 (0.03) 
ARC-1834 -7.56 (0.03) 
ARC-1835 -7.88 (0.03) 
ARC-1839 -6.12 (0.04) 
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Appendix 24. Uptake of ARC-1836 and ARC-1837 by HeLa with 1 hour (A-D) and 2 hour 
(E-H) incubation (continues on the next page). A, E – 1 μM ARC-1836; B, F – 1 μM ARC-
1837; C,G – 10 μM ARC-1836; D, H – 10 μM ARC-1837. The required intensity of the light 
source for ARC-1836 was 2.5 times higher than for ARC-1837 due to weaker fluorescence 
signal. The images are pseudocoloured. 
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